UPDATE: Shares of Sagent Pharmaceuticals Respond to Bank of America's Upgrade

In a report published Friday, Bank of America Merrill Lynch analyst Gregg Gilbert upgraded Sagent Pharmaceuticals (NASDAQ: SGNT ) from Neutral to Buy and lowered the price target from $26.00 to $25.00 noting favorable risk-reward on the stock's pullback. Gilbert commented on the limited downside if Sagent's quarterly performance remains